Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

Experimental Eye Research

Volumn 64, Issue 6, 1997, Pages 971-978

  Kenyon, Bärbel M ^a   Browne, Fiona ^a   D'Amato, Robert J ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Angiogenesis; Cornea; Growth factor; Neovascularization; Thalidomide; Tumor necrosis factor alpha

Indexed keywords

THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CORNEA DISEASE; FEMALE; MACROPHAGE FUNCTION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; RACEMIC MIXTURE; RAT; STATISTICAL ANALYSIS; TERATOGENICITY;

EID: 0031171663     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1006/exer.1997.0292     Document Type: Article

References (39)

1. Blascke, G. Kraft, H. P. Fickentscher, K. Köhler, F. 1979, Chromatographische racemattrennung von thalidomid und teratogene wirkung der enantiomere. Arzneim. Forsch/Drug Res. 29, 1640, 2.
2. Cahen, R. 1964, Evaluation of the teratogenicity of drugs. Clin. Pharmacol. Ther. 5, 480, 514.
3. Carlesimo, M. Giustini, S. Rossi, A. Bonaccorsi, P. Calvieri, S. 1995, Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J. Am. Acad. Derm. 32, 866, 9.
4. D'Amato, R. J. Loughnan, M. S. Flynn, E. Folkman, J. 1994, Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 91, 4082, 5.
5. 14, Biochem. J. 1045, 565, 9.
6. Fabro, S. Smith, R. Williams, R. 1967b, Toxicity and teratogenicity of optical isomers of thalidomide. Nature, 215, 296, 8.
7. Ferrar, N. Henzel, W. J. 1989, Pituitary follicular cells secrete a novel heparin binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 162, 851, 8.
8. Field, E. O. Gibbs, J. E. Tucker, D. L. Hellmann, K. 1966, Effect of thalidomide on graft-versus-host reaction. Nature, 211 (5055), 1308, 10.
9. Friedlander, M. Brooks, P. C. Shaffer, R. W. Kincaid, C. M. Varner, J. A. Cheresh, D. A. 1995, Definition of two angiogenic pathways by distinct alpha integrins. Science, 70, 1500, 2.
10. Gardner-Medwin, J. M. Smith, N. J. Powell, R. J. 1994, Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann. Rheumatol. Disease, 53 (12), 828, 32.
11. Gershbein, L. L. 1991, The thalidomide analog EM12, enhances 1,2-dimethyhydrazine induction of rat colon adenocarcinomas. Cancer Letter, 60, 129, 33.
12. Guex-Crosier, Y. Pittet, N. Herbort, C. P. 1995, The effect of Thalidomide and Supidimide on endotoxin-induced uveitis in rats. Graefe's Arch. Klin. Exp. Ophthalmol. 233 (2), 990, 3.
13. -1, Terato. Carcino. Mut. 14, 115, 22.
14. Jackson, A. Schumacher, H. J. 1980, Identification of urinary metabolites of EM12N, Can. J. Pharmacol. Sci. 15 (2), 21, 3.
15. Kean, W. F. Lock, C. Howard-Lock, H. E. 1991, Chirality in antirheumatic drugs. Lancet, 338, 1565, 8.
16. Kenyon, B. M. Voest, E. E. Chen, C. Flynn, E. Folkman, J. D'Amato, R. J. 1996, A model of angiogenesis in the mouse cornea. Invest. Ophthalmol. Vis. Sci. 37, 1625, 32.
17. Kocher-Becker, U. Kocher, W. 1982, Teratogenic activity of a hydrolytic thalidomide metabolite in mice. Naturwissenschaften, 69, 191, 2.
18. Lenz, W. 1962, Thalidomide and congenital abnormalities. Lancet, 1, 45.
19. McBride, W. G. 1961, Thalidomide and congenital abnormalities. Lancet, 2, 1358.
20. Moreira, A. Sampaio, E. Zmuidzinas, A. Frindt, A. Smith, K. Kaplan, G. 1993, Thalidomide exerts its inhibitory action on tumor necrosis alpha (TNF-alpha) by enhancing mRNA degradation. J. Exp. Med. 177, 1675, 80.
21. Neubert, R. Hinz, N. Thiel, R. Neubert, D. 1996, Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide. Life Sci. 58 (4), 295, 316.
22. Nishimura, K. Hashimoto, Y. Iwasaki, S. 1994, (S)-form of alpha-methyl-N, Chem. Pharmacol. Bull. 42 (5), 1157, 9.
23. Sampaio, E. Sarno, E. Galilly, V. Cohn, Z. A. Kaplan, G. 1991, Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 173, 699, 703.
24. Schandene, L. Vandenbussche, P. Crusiaux, A. Alegre, M. L. Abramowitcz, D. Dupont, E. Content, J. Goldman, M. 1992, Differential effects of pentoxifylline on the production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) by monocytes and T cells. Immunology, 76, 30, 4.
25. Schmahl, H. J. Nau, H. Neubert, D. 1988, The enantiomers of the teratogenic thalidomide analogue EM12: 1. Ciral inversion and plasma pharmacokinetics in the marmoset monkey. Arch. Toxicol. 62, 200, 4.
26. Schmahl, H. Heger, W. Nau, H. 1989, The enantiomers of the teratogenic thalidomide analogue EM12: 2. Chemical stability, stereoselectivity of metabolism and renal excretion in the marmoset monkey. Toxicol. Lett. 45, 23, 33.
27. Schroder, M. Risau, W. Hallman, R. Gautschi, P. Bohlen, P. 1987, Tumor necrosis factor alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc. Nat. Acad. Sci. U.S.A. 84, 5277, 81.
28. Schumacher, H. Smith, R. I. Williams, R. T. 1965a, The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br. J. Pharmacol. Chemother. 25, 324, 37.
29. Schumacher, H. Smith, R. Williams, R. T. 1965b, The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br. J. Pharmacol. 25, 338, 51.
30. Schumacher, H. Blake, D. Gurian, J. Gillette, J. 1967, A comparison of the teratogenic activity of thalidomide in rabbits and rats. J. Pharmacol. Exp. Therap. 160 (1), 189, 200.
31. Schumacher, H. J. Blake, D. A. Gillette, J. R. 1968, Disposition of thalidomide in rabbits and rats. J. Pharmacol. Exp. Ther. 160 (1), 201, 11.
32. Schumacher, H. Terapane, J. Jordan, R. Wilson, J. G. 1972, The teratogenic activity of a thalidomide analog, EM 12, in rabbits, rats and monkeys. Teratology, 5, 233, 40.
33. Scott, W. J. Fradkin, R. Wilson, J. G. 1970, Non-confirmation of thalidomide induced teratogenesis in rats and mice. Teratology, 5, 33, 6.
34. Sheskin, J. 1965, Further observations with thalidomide in lepra reactions. Leprosy Review, 36, 183, 7.
35. Sheskin, J. 1980, The treatment of lepra reactions in lepromatous leprosy. Fifteen years' experience with thalidomide. Int. J. Derm. 19, 318, 22.
36. Shing, Y. Folkman, J. Sullivan, R. Butterfield, C. Murray, J. Klagsbrun, M. 1984, Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science, 223, 1296, 9.
37. Sunderkotter, C. Roth, J. Sorg, C. 1990, Immunohistochemical detection of bFGF and TNF-alpha in the course of inflammatory angiogenesis in the mouse cornea. Am. J. Pathol. 137, 511, 15.
38. Szabo, K. T. Steelman, R. L. 1967, Effects of maternal thalidomide treatment on pregnancy, fetal development, and mortality of the offspring in random-bred mice. Am. J. Vet. Res. 28 (127), 1823, 8.
39. Vogelsang, G. B. Farmer, E. R. Hess, A. D. Altamonte, V. Beschoner, W. E. Jabs, D. A. Corio, R. L. Levin, L. S. Wingard, J. R. Santos, G. W. 1992, Thalidomide for the treatment of chronic graft-versus-host disease. N. Engl. J. Med. 326, 1055, 8.